新開源(300109.SZ):參股公司注射用人白介素-2(高親和型複合物)在中國獲批臨牀
格隆匯6月10日丨新開源(300109.SZ)公佈,參股公司北京良遠生物醫藥研究有限公司(簡稱“良遠生物”)研發的注射用人白介素-2(高親和型複合物)獲得國內臨牀試驗默示許可,適應症為晚期實體瘤。注射用人白介素-2(高親和型複合物,HighAffinityComplex,HAC;研發代號LYC001),是中國本土原創、全球首款採用高親和層級組裝(HighAffinityHierarchicalAssembly)技術平台研發的針對多種實體腫瘤的全新藥物,標誌着高親和型複合物(HAC)這一新的遞送系統和製劑類型正式由概念進入臨牀試驗驗證。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.